Skip to content
Sharism- Lifestyle
Author:
DBV Technologies S.A.
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
July 6, 2026
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
June 29, 2026
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
June 23, 2026
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
June 9, 2026
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
June 8, 2026
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 5, 2026
DBV Technologies Announces the Results of its 2026 Combined General Meeting
June 3, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026
June 3, 2026
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
June 2, 2026
Combined General Meeting of June 3, 2026
May 13, 2026
1
2
Next Page
→